Sunday, August 03, 2025 4:04:59 PM
gemini ai :"is tumor treatment fie?ld fluidic properties related
Yes, the fluidic properties of the body are directly related to the effectiveness and distribution of Tumor Treating Fields (TTFields) and are a key consideration for treatment.
The Role of Body Fluids
TTFields are low-intensity alternating electric fields that are applied externally to the skin. To reach the tumor, these fields must travel through various body tissues, which have different electrical properties. The key fluidic properties that influence this are:
Conductivity: Body fluids, such as cerebrospinal fluid, urine, pleural fluid, and ascites, have much higher electrical conductivity than solid tissues like bone, muscle, and fat. This difference in conductivity greatly influences how the TTFields propagate.
Propagation: The electric fields tend to follow the path of least resistance. Therefore, they will be "channeled" through areas with higher conductivity. This can either intensify the field at the tumor site if the tumor is surrounded by a highly conductive fluid, or attenuate it if the fluid is located in a different area.
Impact on Treatment Planning
Because of this, the fluidic properties of the body are a critical factor in treatment planning.
Computational Modeling: Clinicians use finite element analysis (FEA) to create patient-specific 3D models from MRI and CT scans. These models account for the different electrical properties of various tissues and fluids.
Array Placement: By simulating how the electric fields will propagate through the body's fluids, the models help determine the optimal placement of the transducer arrays on the patient's skin to maximize the field intensity at the tumor site. This personalized approach is crucial because a one-size-fits-all solution would not be effective.
In summary, TTFields do not physically affect the motion of fluids, but the electrical properties of the body's fluids have a significant and measurable impact on the propagation and delivery of TTFields. This relationship is a critical component of how this therapy is planned and administered to patients."
Recent NVCR News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:33:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:32:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:32:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:31:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:31:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:31:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 09:31:04 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2026 09:06:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 10:54:58 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 10:53:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 10:42:44 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2026 10:13:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 09:11:29 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/02/2026 10:40:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/02/2026 09:14:39 PM
- Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer • Business Wire • 03/02/2026 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/27/2026 10:13:31 PM
- Novocure to Participate in 2026 Leerink Global Healthcare Conference • Business Wire • 02/27/2026 09:30:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/26/2026 12:05:53 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 12:01:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 12:01:34 PM
- Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update • Business Wire • 02/26/2026 12:00:00 PM
- Novocure shares rise after Medicare billing privileges reinstated • IH Market News • 02/25/2026 04:16:56 PM
- Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026 • PR Newswire (Canada) • 02/25/2026 02:00:00 PM
- Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026 • PR Newswire (US) • 02/25/2026 02:00:00 PM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
RENI Completes Due Diligence on Target Acquisition; Confirms Strong Asset Base and Operational Performance • RENI • Mar 5, 2026 10:15 AM
BlackStar Engages in Talks with U.S. Senate Banking Committee Team Covering the Digital Asset Market Clarity Act • BEGI • Mar 4, 2026 4:47 PM
